Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin plus insulin glargine versus insulin aspart 30 in inadequately controlled type 2 diabetes
ChiCTR-TRC-12002676Phase 4Completed
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Dec 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sitagliptin, insulin glargine and insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoints: blood glucose, HbA1c and 3 more. Started Dec 2012; status: completed.
02
Drugs
sitagliptininsulin glargineinsulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR-TRC-12002676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002676.